Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPRWGet Free Report) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 16,800 shares, a drop of 11.1% from the January 15th total of 18,900 shares. Based on an average trading volume of 6,200 shares, the days-to-cover ratio is presently 2.7 days.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock traded down $0.01 during trading on Monday, reaching $0.15. The company had a trading volume of 1,348 shares, compared to its average volume of 11,862. The firm’s 50-day simple moving average is $0.18 and its 200 day simple moving average is $0.20. Jasper Therapeutics has a 1-year low of $0.09 and a 1-year high of $0.27.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Further Reading

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.